News | October 23, 2006

Ablation Superior to Amiodarone for the Treatment of First-Episode Symptomatic Atrial Flutter

Radiofrequency ablation is more effective than treatment with amiodarone for the prevention of atrial flutter recurrence in patients who experienced a first symptomatic episode, according to the results of a new study. In addition to the superiority of ablation over amiodarone, there was no increased risk of atrial fibrillation, even in this cohort of older patients, report investigators.

"Based on the registry of clinical studies using radiofrequency ablation to treat atrial flutter, we knew that the percentage of recurrence was very low with ablation and that the number of secondary effects was also very low," lead investigator Dr. Antoine Da Costa (University Jean Monnet, Saint Etienne, France) told heartwire. "Looking at the recurrence rates or the secondary effects with drug treatment, we believed that ablation would fare better, although no there were no studies showing this to be the case. With the number of secondary effects with amiodarone and the percentage of recurrence, compared with radiofrequency ablation, there is clear clinical evidence that radiofrequency ablation is better."

Publishing the findings in the Oct. 17, 2006 issue of Circulation, Dr. Da Costa and colleagues suggest that "radiofrequency ablation should be considered as first-choice therapy even after the first episode of symptomatic atrial flutter."

Despite the positive results, Dr. D George Wyse (University of Calgary, Alberta), who wrote an editorial accompanying the published study, suggests that the efficacy of ablation in preventing the recurrence of atrial flutter as well as the emergence of atrial fibrillation, might be attributable to trial design rather the true differences.

"The major issue is that events contributing to the end points were accumulated during a time in which radiofrequency ablation would be expected to be efficacious but amiodarone would not," writes Wyse. "In a more general sense, it is time that trials of radiofrequency ablation for the treatment of atrial flutter/atrial fibrillation move on from testing the simpler question of antiarrhythmic efficacy to testing the treatment using robust and clinically relevant end points. Although testing for antiarrhythmic efficacy is important at the beginning, perhaps we are nearing the end of the beginning."

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init